AMYPOPHARMA S.r.l. is an Italian biotech start-up company, with the mission to develop functionalized nanoliposomes for new therapeutic approaches to treat protein misfolding disorders.

Protein misfolding disorders, known as amyloidoses, are a group of diseases resulting from abnormal deposition of misfolded proteins (amyloids) in different parts of the body, which ultimately results in progressive organ dysfunction in disorders such as Alzheimer’s disease and other diseases which currently lack effective therapies.

AMYPOPHARMA S.r.l is a spin-off of Università degli Studi di Milano-Bicocca (Unimib) and was founded in 2015 by Professor Massimo Ernesto Masserini and Doctor Francesca Re.

Research activities are based on the scientific work on nanoliposome technology originated from the team lead by the two founders at Unimib.

AMYPOPHARMA S.r.l offers the following products and service:

- Research and development;
- Nanoparticles for the treatment of several severe diseases with unmet medical needs.

Team
- Maria Gabriella Camboni
- Massimo Ernesto Masserini
- Francesca Re
- Marco Sardina

Sector
Life Science & Biotechnology

Support
In 2018, BiovelocITa has invested in AMYPOPHARMA with the objective to accelerate the development of nanoparticles for the treatment of several severe diseases with unmet medical needs.

Contact
Mail: info@amypopharma.com
Telephone: +39 02 83991350
Address: Via Gioberti 8, 20123, Milan, Italy.